SG11202102987VA - Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use - Google Patents

Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use

Info

Publication number
SG11202102987VA
SG11202102987VA SG11202102987VA SG11202102987VA SG11202102987VA SG 11202102987V A SG11202102987V A SG 11202102987VA SG 11202102987V A SG11202102987V A SG 11202102987VA SG 11202102987V A SG11202102987V A SG 11202102987VA SG 11202102987V A SG11202102987V A SG 11202102987VA
Authority
SG
Singapore
Prior art keywords
thieno
methods
pyridine derivatives
udp glycosyltransferase
glycosyltransferase inhibitors
Prior art date
Application number
SG11202102987VA
Other languages
English (en)
Inventor
Sungtaek Lim
Jr Robert H Barker
Mary A Cromwell
Elina Makino
Bradford Hirth
John JIANG
Sachin Maniar
Mark Munson
Yong-Mi Choi
Sukanthini Thurairatnam
Kwon Yon Musick
James Pribish
Michael Angelastro
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of SG11202102987VA publication Critical patent/SG11202102987VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202102987VA 2018-10-01 2019-10-01 Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use SG11202102987VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862739405P 2018-10-01 2018-10-01
PCT/US2019/054085 WO2020072504A1 (en) 2018-10-01 2019-10-01 Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
SG11202102987VA true SG11202102987VA (en) 2021-04-29

Family

ID=68296740

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102987VA SG11202102987VA (en) 2018-10-01 2019-10-01 Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use

Country Status (15)

Country Link
US (1) US11098056B2 (cg-RX-API-DMAC7.html)
EP (1) EP3861000A1 (cg-RX-API-DMAC7.html)
JP (1) JP7545979B2 (cg-RX-API-DMAC7.html)
KR (1) KR102903997B1 (cg-RX-API-DMAC7.html)
CN (1) CN113423711B (cg-RX-API-DMAC7.html)
AU (1) AU2019355870B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021005914A2 (cg-RX-API-DMAC7.html)
CA (1) CA3114722A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021005738A2 (cg-RX-API-DMAC7.html)
IL (1) IL281811B2 (cg-RX-API-DMAC7.html)
MA (1) MA53043B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021003794A (cg-RX-API-DMAC7.html)
SG (1) SG11202102987VA (cg-RX-API-DMAC7.html)
TW (1) TWI821426B (cg-RX-API-DMAC7.html)
WO (1) WO2020072504A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230157981A (ko) * 2021-02-19 2023-11-17 칼비스타 파마슈티컬즈 리미티드 인자 xiia 저해제
EP4483954A1 (en) * 2023-06-29 2025-01-01 Masarykova Univerzita Substituted thieno [3,2-b]pyridines as inhibitors of protein kinases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
WO2001010842A2 (en) * 1999-08-04 2001-02-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
FR2821356A1 (fr) * 2001-02-23 2002-08-30 Cerep Nouveaux derives d'arylcarbamates et d'arylurees, preparations et utilisations
SI2215094T1 (sl) * 2007-11-15 2016-05-31 Ym Biosciences Australia Pty Ltd N vsebujoče heterociklične spojine
AU2010210426B2 (en) * 2009-02-06 2015-06-11 Imago Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
KR20130131461A (ko) * 2011-03-07 2013-12-03 폰다지오네 텔레톤 Tfeb 변종 및 그의 용도
CA3199430A1 (en) * 2015-01-16 2016-07-21 The General Hospital Corporation Compounds for improving mrna splicing
WO2017112777A1 (en) * 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017192930A1 (en) * 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
CA3025943A1 (en) 2016-06-10 2017-12-14 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
KR20190070972A (ko) * 2016-11-02 2019-06-21 얀센 파마슈티카 엔.브이. Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 유도체
WO2018118838A1 (en) * 2016-12-20 2018-06-28 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
BR112019023109A2 (pt) 2017-05-04 2020-05-26 Glenmark Pharmaceuticals S.A. Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo
KR102736865B1 (ko) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물

Also Published As

Publication number Publication date
AU2019355870A1 (en) 2021-05-20
TWI821426B (zh) 2023-11-11
CO2021005738A2 (es) 2021-05-10
MX2021003794A (es) 2021-09-08
US11098056B2 (en) 2021-08-24
TW202035419A (zh) 2020-10-01
JP2022508523A (ja) 2022-01-19
JP7545979B2 (ja) 2024-09-05
CN113423711A (zh) 2021-09-21
KR102903997B1 (ko) 2025-12-26
BR112021005914A2 (pt) 2021-06-29
CN113423711B (zh) 2024-03-15
IL281811B1 (en) 2024-11-01
WO2020072504A1 (en) 2020-04-09
MA53043A1 (fr) 2022-08-31
US20200102324A1 (en) 2020-04-02
MA53043B2 (fr) 2024-05-31
EP3861000A1 (en) 2021-08-11
CA3114722A1 (en) 2020-04-09
IL281811A (en) 2021-05-31
IL281811B2 (en) 2025-03-01
KR20210087033A (ko) 2021-07-09
AU2019355870B2 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
HUE061989T2 (hu) Szubsztituált tieno[2,3-D]pirimidin származékok mint menin-MLL inhibitorai és alkalmazási eljárások
SG11202101148UA (en) PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES
IL289439B2 (en) History of thieno[3,2-c] and thieno[2,3-c] and pharmaceutical preparations containing them
SG11201704521SA (en) Thieno[2,3-c]pyrrol-4-one derivatives as erk inhibitors
ZA201705802B (en) 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
PT3712152T (pt) Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
PL3371185T3 (pl) Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych
IL263511B (en) H1–pyrazolo[4, 3–b]pyridines as pde1 inhibitors
IL251780B (en) Derivatives of 5-(3-hydroxy-propyn-1-yl)-3-(2-amino-pyrimidinyl)-h1-pyrrolo[c-3,2] pyridine and pharmaceutical preparations containing them
IL281811A (en) Thiano[3,2-B]pyridine derivatives as UPD glycosyltransferase inhibitors and methods of use
IL275290B2 (en) Combined treatments that include the administration of h1 - pyrazolo[4, 3-b]pyridines
IL275293B1 (en) Combined treatments that include the administration of h1 - pyrazolo[4, 3-b]pyridines
HK40058382A (en) Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use
EP3302060A4 (en) Pyrazolo[4,3-c]quinoline derivatives for inhibition of -glucuronidase
PT4313293T (pt) Derivados de tetraidrotieno piridina como inibidores de ddrs
IL287417A (en) Cytidine derivatives and methods for preparing cytidine derivatives
EP3426352A4 (en) CAMPTOTHECIN DERIVATIVES AND USES THEREOF
HK40055527A (en) Oxynitidine derivatives useful as inhibitors of topoisomerase ib (top1) and/or tyrosyl-dna phosphodiesterase 1 (tdp1)
IL306062A (en) History of tetrahydrothianopyridine as DDRS inhibitors
PL4313994T3 (pl) Pochodne tetrahydrotienopirydyny jako inhibitory DDR
HK40023787A (en) Type ii topoisomerase inhibitors and methods of making and using thereof
NZ760548A (en) Compositions and methods of modulating short-chain dehydrogenase activity
HK40029730A (en) Pyridinone derivatives and their use as selective alk-2 inhibitors